Deutsche Bank Defends Gilead Sciences (GILD) on Sector Setback
Tweet
Share
E-mailGet Alerts GILD Hot Sheet
Price: $131.27 +4.21%
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Rating Summary:
36 Buy, 7 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 0 | Down: 0 | New: 2
Join SI Premium – FREE
Deutsche Bank commented on Gilead Sciences (NASDAQ: GILD) following news in the sector from Idenix Pharmaceuticals Inc. (Nasdaq: IDIX), which said the FDA placed hepatitis C drug IDX184 on partial clinical hold due to a serious cardiac-related adverse event.
The firm said they spoke with GILD management and the company believes the concerns with IDX184 are drug-specific, not on entire nuke class. GILD said they have not been contacted by the FDA.
The analyst comments: "Notably, GS-7977 has been dosed in over 1000 patients for 12 weeks. Recall, IDX 184 had only been tested in 67 patients for 2 weeks. Furthermore, GS-7977 has already successfully completed a thorough QTC study. This provides us with significant comfort that GS-7977 does not have cardiac issues. From speaking with different thought leaders in the HCV space, it is our sense that the FDA becomes more comfortable when >200 patients have been dosed. Gilead reiterated that it paid $11B for GS-7977 due to its significant safety database."
The firm reiterated their Buy rating and price target of $68.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.97 yesterday.
The firm said they spoke with GILD management and the company believes the concerns with IDX184 are drug-specific, not on entire nuke class. GILD said they have not been contacted by the FDA.
The analyst comments: "Notably, GS-7977 has been dosed in over 1000 patients for 12 weeks. Recall, IDX 184 had only been tested in 67 patients for 2 weeks. Furthermore, GS-7977 has already successfully completed a thorough QTC study. This provides us with significant comfort that GS-7977 does not have cardiac issues. From speaking with different thought leaders in the HCV space, it is our sense that the FDA becomes more comfortable when >200 patients have been dosed. Gilead reiterated that it paid $11B for GS-7977 due to its significant safety database."
The firm reiterated their Buy rating and price target of $68.00.
For an analyst ratings summary and ratings history on Gilead Sciences click here. For more ratings news on Gilead Sciences click here.
Shares of Gilead Sciences closed at $57.97 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Deutsche Bank Resumes Kloeckner & Co SE (KCO:GR) at Hold
- Freedom Broker Starts Unity Bancorp (UNTY) at Hold
- Raymond James Upgrades Aecon Group (ARE:CN) (AEGXF) to Outperform
Create E-mail Alert Related Categories
Analyst Comments, Trader TalkRelated Entities
Deutsche BankSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
